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Abstract
After contusion spinal cord injury (SCI), astrocytes become reactive and form a glial scar. While this reduces spreading of the
damage by containing the area of injury, it inhibits regeneration. One strategy to improve the recovery after SCI is therefore
to reduce the inhibitory effect of the scar, once the acute phase of the injury has passed. The pleiotropic cytokine
interleukin-6 (IL-6) is secreted immediately after injury and regulates scar formation; however, little is known about the role
of IL-6 in the sub-acute phases of SCI. Interestingly, IL-6 also promotes axon regeneration, and therefore its induction in
reactive astrocytes may improve regeneration after SCI. We found that IL-6 is expressed by astrocytes and neurons one
week post-injury and then declines. Using primary cultures of rat astrocytes we delineated the molecular mechanisms that
regulate IL-6 expression and secretion. IL-6 expression requires activation of p38 and depends on NF-kB transcriptional
activity. Activation of these pathways in astrocytes occurs when the PI3K-mTOR-AKT pathway is inhibited. Furthermore, we
found that an increase in cytosolic calcium concentration was necessary for IL-6 secretion. To induce IL-6 secretion in
astrocytes, we used torin2 and rapamycin to block the PI3K-mTOR pathway and increase cytosolic calcium, respectively.
Treating injured animals with torin2 and rapamycin for two weeks, starting two weeks after injury when the scar has been
formed, lead to a modest effect on mechanical hypersensitivity, limited to the period of treatment. These data, taken
together, suggest that treatment with torin2 and rapamycin induces IL-6 secretion by astrocytes and may contribute to the
reduction of mechanical hypersensitivity after SCI.
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Introduction
The physiological outcome after spinal cord injury (SCI) is the
result of a coordinated response of many cell types. Astrocytes play
a key role in the scar formation that follows SCI [1]. During this
process, astrocytes interact with microglia and immune cells to
isolate and clear damaged tissue and to reestablish normal
homeostasis of the spinal cord [2,3]. In order to communicate
with each other and regulate the surrounding environment these
cells secrete cytokines [4]. Interestingly, the same signaling
molecules can be secreted by different cell types at different time
points after injury [5].
Interleukin-6 (IL-6) is a pleiotropic cytokine and its effects on
SCI depend mostly on the temporal expression and the balance
between survival-promoting and pro-inflammatory effects. Fol-
lowing SCI, microglia and macrophages secrete IL-6, which is
thought to play a negative role in regeneration by recruiting
immune cells to the site of injury and by promoting glial scar
formation [6]. However, IL-6 expression also has positive roles in
regeneration by promoting synaptic rearrangements, axon sprout-
ing, and reducing tissue loss [7,8].
In order to implement its function, IL-6 needs to be released
into the extracellular space; hence, regulation of transcription-
translation as well as of secretion are important for IL-6 mediated
responses [9]. The Nuclear Factor-kB (NF-kB) is a strong inducer
of IL-6 mRNA [10]. Various signaling cascades intersect with NF-
kB to tightly regulate its activity [11] For example, the mitogen
activated protein kinase (MAPK) p38, the phosphoinositide-3-
kinase (PI3K) and the mechanistic target of rapamycin (mTOR)
pathways. While activation of p38 promotes IL-6 expression, both
PI3K and mTOR can exert inhibitory effects, depending on the
cell type examined [12,13].
After synthesis, IL-6 accumulates in secretory vesicles that upon
stimulation fuse with the plasma membrane, releasing IL-6 into
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the extracellular space [9]. Increased intracellular calcium (Ca2+) is
required for exocytosis. In cells, the endoplasmic reticulum (ER) is
the main storage of intracellular Ca2+, which can be released into
the cytoplasm through inositol-1,2,5-tris-phosphate receptors
(InsP3R) or ryanodine receptors (RyR) [14]. Both receptor types
are regulated by accessory proteins, such as the FK506-binding
proteins (FKBP)-12 [15]. FKBP12 inhibits RyR mediated Ca2+
release while its effect on InsP3Rs is cell dependent and can either
be to promote or inhibit Ca2+ release [16–18]. Interestingly,
patients harboring mutations that increase the leakiness of RyRs
show increased IL-6 secretion [19].
Although it has been shown that astrocytes secrete IL-6 [20], the
signaling pathways involved are not well characterized. Hence,
this study aims to understand which signaling pathways are
important in the regulation of IL-6 in astrocytes in order to
identify or develop drugs that can be used to up-regulate and/or
down-regulate its secretion in vivo.
Experimental Procedures
Antibodies and other Reagents
Antibodies. The following commercially available antibodies
(Cell Signaling Technologies) were used: pERK (#9101), pAKT-
S473 (#9271), pAKT-T308 (#2965), AKT (#9272), Cleaved
caspase-3 (#9661), GAPDH (#2118), pS6(S235/236) (#4858),
p-p38(#8690), pJNK (#4668). IL-6 (Abcam, ab6672), Aldh1L1
(NeuroMab, N103/31), Vimentin (V6630) and GFAP (G-3893)
(Sigma), ED1 (MCA341R) and OX42 (MCA275R) (Serotec), and
NeuN (Chemicon MAB377). Secondary antibodies for immuno-
histochemistry and fluorescent western blotting (Life Technology),
and HRP-conjugated secondaries (Sigma) were used.
Drugs. Rapamycin was commercially available (LC labora-
tories) as was LY294002 and FK506 (Tocris), the AKT inhibitor
(Calbiochem) and Bapta-AM (Life Technology). Torin1 and
torin2 were synthesized by Dr. Liu (Department of Cancer
Biology, Dana-Farber Cancer Institute, Boston, MA).
Reagents. These included Complete mini (protease inhibitor)
and phosphostop (phosphatase inhibitor) (Roche). All other
reagents were from Sigma.
Plasmids
pTK-RL (Stratagene), p1168huIL6P-Luc+ (wt IL-6 promoter,
LMBP 4495) and p1168hIL6mNFkB-Luc+ (NFkB mutated
promoter, LMBP 4496) (Belgian Coordinated Collections of
Microorganisms (BCCM/LMBP)), and pRIL6C.94 (ATCC,
ATCC-37681) were used.
Astrocyte Cultures
Astrocyte cultures were prepared from spinal cords of adult
male Sprague-Dawley rats (P65 to P70, weighing 200–250 grams
Scanbur) using a method previously described [21]. For western
blotting and real-time PCR, the cells were trypsinized and replated
in 6-well plates (40,000 cells/well). The cultures were used for
experiments when confluent (typically within 4–6 days). For
mesoscale experiments, the cells were replated in 24-well plates
(20,000 cells/well) and used when confluent (typically 2 days after
plating). Before drug treatment the cells were incubated for 48
hours in growth-factor-free Dulbecco’s modified Eagle’s medium
(GF Free DMEM), supplemented with 1% penicillin-streptomycin
and 1% sodium pyruvate (Life Technologies).
Spinal Cord Contusion Injury
Animal work was approved by the North Stockholm Animal
Ethics Committee (permit # N429/09 and N479/11). Female rats
(220 g, Scanbur, Sweden) were group-housed 4 animals per cage,
and kept on a 12-hour light/dark cycle with food and water ad
libitum. Spinal cord injury was done as previously described [22]
with the Keck Center for Neurosciences impactor (NYU impactor)
using a 10 g weight dropped from a height of 25 mm onto the
dorsal surface of the exposed spinal cord. After recording BBB
scores (see below), withdrawal thresholds evoked by touch
stimulus, and body weights for the first week post-injury, animals
were divided into 5 treatment groups: naı¨ve (N = 4), sham (N = 6),
vehicle (N = 6), torin2 (N = 6), and torin2+rapamycin (N = 8).
Torin2 alone (4 mg/kg) or in combination with rapamycin
(1.5 mg/kg) was administered orally by gavage once a day starting
at day 15 after injury and ending at day 29. In sham operated rats
only the laminectomy was performed. For all of the following
experimental procedures and analyses, including behavioral
testing and histological analyses, experimenters were blinded to
the treatment groups.
Locomotor Evaluation
The Basso, Beattie, Bresnahan (BBB) locomotor rating scale
[23] was used to evaluate hindlimb locomotor function in an open
field on a weekly basis for 6 weeks. All experimenters involved with
BBB evaluation were blinded to treatment group identity.
Assessment of Mechanical Hypersensitivity
Rats were habituated to the testing enclosure twice before the
experiment started. Mechanical hypersensitivity was assessed three
times prior to the surgery, once two weeks post-surgery to confirm
the decrease in hind paw withdrawal threshold, and six times
during the drug-treatment period on weeks 3–6 post-injury. Rats
were placed in individual Plexiglas chambers on top of a wire mesh
surface and allowed to acclimatize for 30 minutes prior to testing.
Hind paw withdrawal thresholds were assessed by using calibrated
von Frey filaments (Stoelting) with logarithmically incremental
force of 0.4, 1, 2, 4, 6, 8, 10 and 15 g. A cut-off of 15 g was applied
in order to avoid tissue damage, thus supra-threshold responses
were not registered. Each filament was pressed perpendicularly
against the plantar surface of the hind paw and held on for
approximately 3 seconds. A positive response was recorded if the
paw was withdrawn. The filaments were used according to the
‘‘up-down’’ method [24] and the 50% probability of withdrawal
threshold described by Chaplan and co-workers [25] was
calculated in grams for each hind paw and averaged. Mechanical
hypersensitivity, the percent change from the average of the
baseline values was also calculated.
Tissue Processing
Naı¨ve and injured rats at 6 hours, 1, 2, and 3 weeks after SCI
(N = 4 for each condition) were anaesthetized with 50 mg/kg
pentobarbital and perfused with 50 ml of calcium free Tyrode’s
solution containing 0.1 ml heparin (5000 IE/ml) followed by
50 ml of 4% formaldehyde in PBS (PFA). For in situ hybridization
and immunohistochemistry, spinal cords were dissected and post-
fixed in 4% PFA at RT for 1 h and stored in 10% sucrose in PBS
at 4uC. Spinal cords were then cut in 7 mm segments.
In situ Hybridization
RNA probes for rat IL-6 mRNA were prepared as previously
described [26]. IL-6 mRNA in situ hybridization was performed in
spinal cord sections of naı¨ve and injured animals at 6 hours, 1, and
2 weeks after SCI. Briefly, sections were permeabilized in PBST
(PBS, 0.3% Tween-20), followed by overnight hybridization at
45uC with 10 ng/ml of riboprobe in hybridization solution (4 mM
Torin2+Rapamycin Induce IL6 Secretion in Astrocyte
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92649
Figure 1. IL-6 is expressed in the spinal cord after contusion injury. After spinal cord contusion injury, IL-6 is upregulated in cells of the spinal
cord. A, Cartoon depicting: (I) the 7 mm long segments (rostral, caudal, epicenter) in which the injured spinal cord is dissected for analysis. (II)
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Tris-HCl pH 7.5, Poly-A 0.5 mg/ml, salmon sperm 0.5 mg/ml,
50% formamide, 20% dextran sulphate, 0.1 M DTT, 0.3 M
NaCl, 1X Denhardt’s solution, 1 mM EDTA pH 8.0). Next,
sections were washed twice for 15 min in 2X SSC at 45uC,
4615 min with 0.1X SSC at 55uC, once for 10 min at RT in 5X
MAB (2.5 M maleic acid; 3.75 M NaCl; pH 7.5), and three times
for 10 min at RT in 1X MABT (0.5 M maleic acid; 0.75 M NaCl;
0.1% Tween-20; pH 7.5). Sections were then incubated with
blocking solution (1X MAB, 20% donkey serum, 2% blocking
agent; 0.1% Tween-20) for 1 h at RT followed by overnight
incubation at RT with anti-digoxigenin antibody conjugated to
alkaline phosphatase (Roche) (1:2000) in blocking solution. After
washing 4620 min in 1X MABT and 3610 min in B3 (0.1 M
Tris-HCl, pH 9.5; 0.1 M NaCl; 50 mM MgCl2; 0.1% Tween-20),
sections were developed for 4 h with NBT/BCIP (Roche) (1:50) in
B3 solution, and images were acquired (Olympus FV1000 CLSM
Olympus).
Immunohistochemistry
Spinal cord sections were permeabilized twice for 5 min with
TBST (TBS, 0.2% Tween-20), blocked for 1 h at RT in blocking
solution (TBST with 5% goat serum), incubated overnight at 4uC
with primary antibodies in blocking solution, and finally incubated
for 1 h at RT with Alexa-conjugated secondary antibodies (Life
Technologies) in blocking solution. DAPI staining was applied for
30 min in blocking solution. Images were acquired using confocal
microscopy (Olympus FV1000 or Zeiss LSM700). Imaris 7.3.0
(Bitplane) was used to quantify the intensity of IL-6, pS6 and pS6/
IL-6 colocalization in GFAP positive cells. In order to identify
GFAP positive cells we first rendered the image stack in 3 D. The
GFAP channel was then selected and the pixels above a minimal
threshold were used to build a 3 D surface. This 3 D surface
isolated the GFAP positive cells. IL-6 and pS6 intensity and pS6/
IL-6 colocalization were quantified inside this GFAP positive
surface. The settings used in the image processing were the same
for all images analyzed. The figures were prepared using
appropriate image handling software (Adobe Illustrator CS5,
Adobe Systems). IL-6 immunofluorescence in the different regions
and segments of the spinal cord was quantified by measuring the
integrated intensity of ROIs selected (Fiji) [27]. The heat map in
Figure 1C was generated using a custom script in python/
matplotlib.
Real-time PCR
All reagents used were commercially available (Life Technol-
ogies). Probe and primer for IL-6 mRNA were ‘‘assay-on-
demand’’ gene expression products (TaqMan Probe and primer
ID Rn00561420_m1). After stimulation with drugs (8 hrs),
astrocytes were washed with PBS and lysate using Trizol. Total
RNA was purified using phenol-chloroform and reversed tran-
scribed using random hexanucleotide primers. PCR amplification
reactions were carried out in 25 ml containing 50 ng of cDNA
(MicroAmp Optical Plates with MicroAmp Optical Caps and the
TaqMan Universal Master Mix). Incubations at 50uC for 2 min
and at 95uC for 10 min were carried out to activate the
polymerase (AmpliTaq polymerase), followed by 40 cycles at
95uC for 15 s and 60uC for 1 min. GAPDH was used as a loading
control for each sample and the standard curve method was used
for quantification [28].
Immunoblotting
Astrocyte cultures were lysed in RIPA buffer (Sigma) containing
protease inhibitors and phosphatase inhibitor cocktails. Samples
were analyzed by SDS-PAGE followed by immunoblotting.
Membranes were incubated with primary antibodies followed by
horseradish peroxidase-conjugated secondary antibodies and ECL
prime chemiluminescence detection reagent (GE). Chemilumines-
cent signal was detected using a Biorad ChemiDocXRS+ (Biorad).
For detection using near-infrared, membranes were incubated
with secondary antibodies (Alexa-680 and Alexa-790) and scanned
(Odyssey scanner, LICOR). Membranes were stripped (ReBlot
Western Blot Recycling Kit, Millipore) before re-probing with a
different antibody.
Transfection and Luciferase Gene Reporter Assay
In reporter gene assays, 106 cells were transiently transfected
(Amaxa nucleofection, VPI-1006, electroporation program T-020)
according to the manufacturer’s instructions. Astrocytes were
transfected with 400 ng of the pRL-TK-Luc plasmid together with
3600 ng of p1168huIL6P-Luc+ or p1168hIL6mNFkB-Luc+ plas-
mid and plated in complete media for 24 hrs. After 24 hours, the
media was replaced with GF-free media for an additional 24
hours. Drugs were then applied and after 24 hours the cells were
lysed in reporter lysis buffer (Promega). Reporter activity was
determined (Promega dual luciferase assay system) according to
manufacturer’s instructions. Firefly and Renilla activities were
detected (Victor2 reader, Wallac). Firefly luciferase values were
normalized for transfection efficiency by means of the Renilla
luciferase activity that is constitutively expressed by pRL-TK.
Cytokine Detection
High sensitivity detection of rat IL-6 was carried out using a
commercially available kit (KC153AKC-1 rat IL-6 ultra-sensitive
kit, Mesoscale discovery, MSD). For cytokine detection in cell
culture supernatant, 20,000 cells/well were plated in 24-well plates
and incubated 2 days until confluent. Culture media was then
replaced with GF-free media. After 48 hours, the GF-free media
was replaced with GF-free media containing drugs. After 24 hours,
the supernatant was collected and centrifuged at 4uC 10,000 rpm
for 5 minutes to remove cell debris. The supernatant was collected
without disturbing the pellet, aliquoted and frozen on dry ice. For
analysis of cytokines in plasma, blood was collected by cardiac
puncture before (naive), 6 hours, 7 days, and 14 days after injury.
The blood was collected in micro container SSB tubes (BD) and
Regions of the spinal cord sections imaged. Dorsal horn (DH), dorsal column (DC), central canal (CC), white matter (WM) and ventral horn (VH). B, IL-6
levels in plasma of animals used for in situ hybridization and immunohistochemistry. Data are presented as mean 6 SEM. ***p,0.001 for the
comparison between naive and injured animals by one-way ANOVA with Bonferroni’s post hoc test (N = 4 per group). C, (I) Representation of the IL-6
protein distribution quantified by immunohistochemistry in spinal cord segments at different time points after injury. Blue indicates the lowest and
red the highest intensity of IL-6 immunofluorescence (arbitrary units, a.u.). R, rostral and C, caudal. (II) Representative images of IL-6 labeled sections
from the C1 region of naı¨ve, sham (1 week after injury) and injured animals. Scale bar = 20 mm. (III) Quantification of IL-6 immunoreactivity in different
regions of the spinal cord at different time points after injury. N = 3 animals for each condition. For each spinal cord segment three sections have
been imaged and fluorescence signal in the regions defined in A(II) was quantified and averaged in each section. D, In situ hybridization with an
antisense IL-6 mRNA probe on sections from rostral, epicenter and caudal segments of spinal cord from naive and injured animals 6 hours, 1, and 2
weeks post-injury. Scale bar = 200 mm. E, High magnification images from sections of the caudal segment shown in D from naive (20X) and 1 week
injured spinal cord animals (20X and 40X). Scale bar = 20 mm for 20X and 40X. (N = 3 in each group).
doi:10.1371/journal.pone.0092649.g001
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Figure 2. Astrocytes express IL-6 1 week after contusion injury. Reactive astrocytes express IL-6 after contusion injury as well as neurons and
microglia/macrophages. A, Immunolabeling of IL-6 (green) and astrocyte markers (magenta) ALDH1L1 (I), vimentin (II) and GFAP (III) in different
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the plasma was separated by centrifugation at 6000 rcf for 90
seconds. After isolation, the plasma was frozen on dry ice.
For cytokine detections in supernatant and plasma samples, we
followed the manufacturer’s instructions with minor modification.
The 96-well plates were incubated with diluent solution with 2%
BSA (25 ml) for 30 minutes at RT on an orbital shaker. Samples
and standards were added (25 ml) and the plate was incubated over
night at 4uC on an orbital shaker. The wells were then washed
three times using 200 ml PBS +0.05%Tween-20. The detection
antibody was added and the plate was incubated for 2 hrs at room
temperature on an orbital shaker. At the end of the incubation the
plate was washed three times using 200 ml PBS +0.05%Tween-20.
Read Buffer (150 ml, MSD) was then added to each well and IL-6
was measured (MSD Sector Imager 2400 plate reader). Raw data
were analyzed using MSD software (Discovery Workbench 3.0). A
4-parameter logistic fit curve was generated using the standards
and the concentration of each sample calculated.
Calcium Measurements
After 48 h starvation and 24 h treatment with torin2 and/or
rapamycin, spinal cord astrocytes were loaded with 5 mM Fura2-
AM and 0.1% Pluronic Acid (F-127 Life Technologies) for 30 min
at 37uC in starving media, rinsed twice, and imaged in Ca2+-free
KREBS-Ringer’s solution (119 mM NaCl, 2.5 mM KCl, 1 mM
NaH2PO4, 2 mM EGTA, 1.3 mM MgCl2, 20 mM HEPES,
11 mM D-glucose) at 37uC. After baseline readings, 3 mM of 4-
chloro-methylphenol (4-cmc) was bath-applied to the cells. mTOR
inhibitors were present during loading and throughout the
duration of the experiment. Images were acquired at 340 nm
and 380 nm at a frequency of 0.5 Hz using an upright widefield
microscope (Zeiss) equipped with a 20x water immersion objective.
Image analysis was done using custom Python scripts.
In situ Detection of Fragmented DNA (TUNEL Assay)
Astrocytes were plated in poly-lysine-coated plates with
transparent bottom for high content screening (BD). After 24
hours, the cells were incubated in GF-free media and 48 hours
later the cells were incubated with GF-free media containing the
drugs. After 24 hours incubation, fragmented DNA was detected
using a commercially available kit (Click-iT TUNEL Alexa Fluor
Imaging Assay, Life Technology) as indicated by the manufactur-
er. The plate was imaged using a cell observer (Zeiss) and the
percentage of TUNEL-positive cells was quantified with a custom
pipeline generated in CellProfiler [29].
Results
Reactive Astrocytes Express IL-6 after Contusion Spinal
Cord Injury
In order to examine IL-6 expression in the spinal cord after
injury, we used a contusion injury model. The corticospinal tract
and other dorsal parts of the spinal cord were damaged by
dropping a weight on the exposed dura using the NYU impactor
[23,30]. We collected spinal cords and plasma from animals at 6
hours, 1, 2, and 3 weeks after injury, control cords were obtained
from sham operated and naı¨ve rats. It has been shown that strong
astrocyte activation is detectable 1 week after contusion injury;
however, the astrocyte scar is fully formed 2–3 weeks post-injury
[31]. Interestingly, IL-6 levels in plasma were already high 6 hours
after injury, but returned to basal by week one (Figure 1B). We
next examined spinal cord sections from the same animals by in
situ hybridization and immunohistochemistry. In order to deter-
mine if IL-6 expression in the spinal cord correlated with the
plasma levels, we divided the spinal cords in 7 mm-long segments
and quantified IL-6 expression by immunohistochemistry
(Figure 1A,C). We found that the IL-6 level was highest at 6
hours after injury and returned to baseline by week two (Figure 1C
(I,II)). Noteworthy, sham surgery (1 week) did not cause an
increase of IL-6 levels in the spinal cord compared to levels in
naı¨ve animals (Figure 1C). Moreover, IL-6 protein was not
homogenously expressed along the spinal cord length; IL-6 was
higher in the epicenter segment while levels were lower rostrally
and caudally (Figure 1C (I)). Interestingly, when the different
regions in the spinal cord sections were examined, IL-6 expression
increased in the gray matter (dorsal and ventral horn) and in the
dorsal column, but no changes were detectable in other regions
(Figure 1C (III)).
In order to determine if cells of the injured spinal cord produce
IL-6, we used in situ hybridization to detect IL-6 mRNA in tissue
sections (Figure 1D–E). An increase of IL-6 mRNA was detectable
in the injury epicenter, both dorsal and caudal to the injury site at
6 hours, 1, and 2 weeks after injury. These areas showed a marked
upregulation of IL-6 mRNA in cells of gray and white matter of
the injured spinal cord as compared to naı¨ve animals (Figure 1D–
E). An IL-6 sense in situ probe was used as a control and specificity
was indicated by lack of signal in naı¨ve tissue and in tissue
harvested 1 and 2 weeks after injury (Figure S1). High
magnification images of spinal cord sections showed that IL-
6 mRNA was expressed in different cell types (Figure 1E).
To determine if astrocytes express IL-6, we assessed the
colocalization of IL-6 immunoreactivity with the pan-astrocytic
marker aldehyde dehydrogenase 1 family member L1 (ALDH1L1)
and markers of reactive astrocytes, such as vimentin and glial
fibrillary acidic protein (GFAP). We found that IL-6 protein
expression colocalized with all three astrocyte markers in all
regions of the spinal cord examined (Figure 2A). However, our in
situ data showed that at 1 week post-injury, IL-6 mRNA was
present in multiple cell types (Figure 1E). Hence, to investigate if
IL-6 was also produced by neurons and/or microglia and
macrophages, we determined the degree of colocalization between
IL-6 and the neuronal marker NeuN and between IL-6 and the
microglia/macrophage markers OX42, and ED1. We found that
IL-6 was not only expressed by reactive astrocytes but also by
neurons of the dorsal and ventral horn (Figure 2B) as well as by
macrophages and microglia in the dorsal column (Figure 2C).
However, at 1 week after injury, macrophages or microglia did not
express IL-6 in the white matter or in any of the other regions of
the spinal cord analyzed (Figure S2).
Because astrocyte properties change during the different phases
of SCI [32], we examined if IL-6 immunoreactivity in astrocytes 1
and 3 weeks after injury (Figure 3A). We found that IL-6
expression in GFAP+ cells was significantly increased at 1 week
(1.160.1 a.u.) and returned to sham levels (0.3860.01 a.u.) at 3
weeks post-injury (0.5960.04 a.u.), indicating that IL-6 was
expressed at the beginning of the astrocyte response but returned
to baseline when the scar was fully formed (Figure 3B).
regions of the caudal segment from spinal cords 1 week after injury. Scale bar = 20 mm. B, Immunolabeling of IL-6 (green) and the neuronal marker
NeuN (magenta) in dorsal and ventral horns of caudal segments from spinal cords 1 week after injury. Scale bar = 20 mm. C, Immunolabeling for IL-6
(green) and the microglia and macrophage markers OX-42 and ED-1 (magenta) in the dorsal column of the caudal segment from spinal cords 1 week
after injury. Scale bar = 20 mm. N = 3 for all conditions.
doi:10.1371/journal.pone.0092649.g002
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Figure 3. mTORC1 activity and IL-6 expression are negatively correlated in SCI. IL-6 expression in reactive astrocytes of the white matter
returns to baseline three weeks after injury, at a time when mTORC1 activation peaks. A, Immunolabeling for pS6 (235/236) (green), IL-6 (magenta),
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mTORC1 Activity and IL-6 Expression are Negatively
Correlated in SCI
Recent reports showed that PI3K and mTOR inhibition
regulate IL-6 expression in immune cells [13,33]. Since mTORC1
is the main regulator of protein translation, we decided to examine
if mTORC1 can regulate IL-6 expression in astrocytes following
injury. As the mTORC1 activity readout, we measured the
phosphorylation level of the downstream target ribosomal protein
S6 by immunofluorescence in GFAP+ cells in tissue sections from
spinal cord collected at 1 and 3 weeks after injury (Figure 3C).
Interestingly, pS6 immunoreactivity negatively correlated with IL-
6 expression in reactive astrocytes of the white matter. pS6 was low
in astrocytes 1 week post-injury (0.2660.06 a.u.), when IL-6 level
was the highest (1.160.1 a.u.), and high at 3 weeks (0.5760.1 a.u.),
when IL-6 expression in astrocytes had returned to baseline
(0.5960.04 a.u.) (Figure 3B,C), suggesting that, in vivo, mTORC1
activity inhibits IL-6 expression. Moreover, no colocalization was
detected between IL-6 and pS6 in GFAP+ astrocytes at any of the
time points analyzed (Figure 3D).
The PI3K-mTOR Pathway Regulates IL-6 Expression in
Cultured Spinal Cord Astrocytes
To increase understanding of the mechanisms that regulate IL-6
production in astrocytes, we used cultured astrocytes from adult
rat spinal cord. More than 99% of these cells express astrocytic
markers [21]. To avoid IL-6 induction, all experiments were
performed with cultures incubated in growth factor free media (GF
free). Noteworthy, the amino acids present in the media were
sufficient to activate PI3K and both mTORC1 and mTORC2
(Figure 4C–D, GF free condition) [34].
We stimulated primary astrocytes with rapamycin for 8 hours
and measured IL-6 mRNA by qPCR in order to determine if
mTORC1 inhibition can also promote IL-6 expression. We found
that rapamycin had no effect on IL-6 mRNA levels (Figure 4A–B).
Even though rapamycin inhibits mTORC1, in astrocytes it also
induces activation of mTORC2 as well as the PI3K downstream
target pyruvate dehydrogenase kinase, isozyme 1 (PDK1), as
shown by an increased phosphorylation of AKT at serine 473
(mTORC2 dependent) and threonine 308 (PDK1 dependent)
(Figure 4C–D). Therefore, in order to inhibit both mTORC1 and
mTORC2, we treated astrocytes with torin1 and torin2, two
analogues that block the ATP binding site of mTOR [35,36].
Interestingly, both torin1 and torin2, at the concentration used
(1 mM), inhibited mTORC1 and mTORC2, as well as AKT
phosphorylation at threonine 308, suggesting inhibition of the
PI3K-PDK1 pathway (Figure 4C–D and data now shown). Torin1
and torin2 treatment increased IL-6 mRNA, suggesting that the
PI3K-mTOR pathway is a negative regulator of IL-6 expression in
astrocytes (Figure 4A–B). Importantly, torin2 treatment did not
show any cell toxicity, as no signs of cell death were observed by
TUNEL assay or by detection of cleaved-caspase 3 by western
blotting (Figure 4E–G).
NF-kB and p38 Mediate the Effect of PI3K-mTOR on IL-6
Expression
The transcription factor NF-kB is a strong inducer of IL-6 [10];
therefore, to determine if PI3K-mTOR inhibition induces IL-6
mRNA through NF-kB regulation, we transfected astrocytes with
a plasmid containing the firefly luciferase gene under the control of
either the wild type hIL-6 promoter (wt) or a hIL-6 promoter in
which the binding site for NF-kB is mutated in order to prevent
the binding of the transcription factor. It has been previously
reported that both promoters are able to drive luciferase
expression in the same way when stimulated by an NF-kB-
independent stimulus [3,37]. The plasmids were co-transfected
with the co-reporter vector pRL-TK. Astrocytes transfected with
the wt hIL-6 promoter showed a strong induction of luciferase
signal after torin2 treatment (472.9697.1%), confirming that
inhibition of PI3K-mTOR regulates IL-6 mRNA transcription
(Figure 5A gray bars). The mutation of the NF-kB binding site
reduced the luciferase signal to baseline (119.2617.8%), indicating
that NF-kB regulates IL-6 transcription (Figure 5A). These data
indicate that the PI3K-mTOR pathway can regulate IL-6
transcription through modulation of NF-kB activity in astrocytes.
Previous work has shown that NF-kB activation requires
phosphorylation and degradation of the inhibitory subunit IkB
by the IkB kinase (IKK). MAPKs can regulate IL-6 mRNA
expression via phosphorylation and activation of IKK. Once
active, IKK acts by phosphorylating and degrading NF-kB
inhibitory subunit IkB, resulting in NF-kB activation [11]. In
order to examine if MAPKs activation is increased after PI3K-
mTOR inhibition, we treated primary cultures of astrocytes with
torin2 and blotted for the activated form of p38, ERK1/2, and
JNK (Figure 5B). Astrocytes maintained in GF free media have a
basal level of p38, ERK1/2, and JNK activation, and torin2
treatment increased p38 phosphorylation (355640%) (Figure 5C),
suggesting that NF-kB activation may result from increased p38
activation. In order to assess if p38 mediates the effect of PI3K-
mTOR on IL-6 expression, we treated primary cultures with the
p38 inhibitor SB203580 (Figure 5D), and found that SB203580
treatment blocked the IL-6 mRNA induction produced by torin2
treatment, suggesting that p38 can regulate IL-6 mRNA
expression in astrocytes (Figure 5D).
PI3K-mTOR Inhibition and Increased Cytosolic Calcium
are Necessary for IL-6 Secretion
We hypothesized that in order to induce IL-6 secretion in
primary cultures of astrocytes, more than one of the molecular
steps involved in regulation of cytokine production would have to
be manipulated. Our data indicate that IL-6 expression in
astrocytes can be induced by PI3K-mTOR inhibition by torin2
(Figure 4B). It has been previously reported that increased
cytosolic Ca2+ through leaky RyRs in the ER promotes IL-6
secretion [19]. Interestingly, even though rapamycin is commonly
used as an mTORC1 inhibitor, it functions by binding FKBP12, a
GFAP (blue), and DAPI (orange) in white matter of the caudal segment of spinal cords from naı¨ve (I), sham (II) and injured animals 1 (III) and 3 (IV)
weeks after injury. For all images, colocalization between IL-6 and pS6 is depicted in white. Scale bar = 20 mM. B, Quantification of IL-6
immunofluorescence in GFAP+ astrocytes in white matter of the caudal segment of the spinal cord from naı¨ve and sham animals and animals 1 and 3
weeks after injury. In each section IL-6 immunofluorescence is normalized to the total GFAP fluorescence signal. Data presented as mean 6 SEM.
***p,0.001 and n.s. (not significant) for the comparison between sham and injured animals and ### p,0.01 for the comparison between 1 week
and 3 weeks after injury by one-way ANOVA and Bonferroni’s post hoc test (N = 3 in each group). C, Quantification of pS6 immunofluorescence in
GFAP+ astrocytes from the white matter of sections from the caudal segment of the spinal cord from naı¨ve and sham animals and animals 1 and 3
weeks after injury. In each section, IL-6 immunofluorescence is normalized for the total GFAP fluorescence signal. Data are presented as mean 6 SEM
(N = 3 in each group). ***p,0.001 for the comparison between sham and injured animals and * p,0.05 for the comparison between 1 week and 3
weeks injured animals by one-way ANOVA with Bonferroni’s post hoc test. D, Quantification of IL-6 and pS6 colocalization in GFAP+ astrocytes from
the white matter of sections from the caudal segment of the spinal cord from naı¨ve, and sham and animals, and animals 1 and 3 weeks after injury.
doi:10.1371/journal.pone.0092649.g003
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Figure 4. The PI3K-mTOR pathway regulates IL-6 expression in cultured spinal cord astrocytes. PI3K-mTOR inhibition with the ATP-
competitive drugs, torin1 and torin2, inhibits AKT and induces IL-6 expression without increasing cell death in primary cultures of adult spinal cord
Torin2+Rapamycin Induce IL6 Secretion in Astrocyte
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e92649
regulator of RyRs gating. Binding of rapamycin to FKBP12 results
in increased open probability of RyRs and increased cytosolic
Ca2+ concentration [15]. Hence, we induced IL-6 expression and
affected RyRs by using a combined treatment of torin2 and
rapamycin. We found that when astrocytes were treated with
torin2/1+rapamycin, IL-6 was detected in the supernatant, but
only when torin2 was used at 1 mM, the concentration at which
also PI3K and PDK1-AKT pathways were inhibited (Figure 6A,C,
4B–C). Moreover, neither torin2 or rapamycin treatment alone
was able to induce IL-6 protein secretion in the supernatant
(Figure 6A), suggesting that in astrocytes an increase in gene
expression and protein secretion are both necessary for IL-6
production. Noteworthy, IL-6 mRNA levels in torin1/2+rapamy-
cin treated astrocytes were not statistically different from the
increase caused by torin1/2 treatment alone, suggesting that the
effect of rapamycin on IL-6 secretion is not caused by an enhanced
IL-6 expression in the combined treatment (Fig. 4A–B).
To confirm that PI3K-mTOR inhibition is necessary for IL-6
secretion, we treated astrocytes with rapamycin together with the
PI3K inhibitor LY294002 at a concentration of 30 mM, which is
known to also inhibit mTOR [38]. Interestingly, LY294002+
rapamycin induced IL-6 secretion (13556703%) at a level
comparable to torin2+rapamycin treatment (13996234%)
(Figure 6B). Since torin2 treatment caused AKT inhibition in
astrocytes (Figure 4C–D), we examined if AKT could be
mediating the effect of PI3K-mTOR in IL-6 secretion. While
the AKT inhibitor alone had no effect on IL-6 secretion, the
combination with rapamycin strongly induced IL-6 in the
supernatant (257661001%), indicating that AKT mediates the
PI3K-mTOR effect on IL-6 secretion (Figure 6B). To confirm that
the effect of rapamycin on IL-6 secretion was independent from its
inhibitory function on mTORC1, but depended on its regulation
of RyRs permeability and cytosolic Ca2+ concentration, we treated
cells with FK506 (Figure 6C). FK506 is a potent immunosuppres-
sant that forms a drug-immunophilin complex with FKBP12,
displacing it from the RyRs [15]. However, the FK506-FKBP12
complex is not able to interact and inhibit mTOR, and thus is
often used as a control to monitor mTOR-independent rapamycin
effects [39]. IL-6 secretion in astrocytes was not affected by
treatment with FK506 (Figure 6C); however, FK506 in combina-
tion with torin2 caused a strong secretion of IL-6 (Figure 6C),
confirming that IL-6 secretion depends on RyRs. In order to
determine whether IL-6 secretion caused by torin2+rapamycin
treatment was Ca2+ dependent, we pre-treated cell cultures for 30
minutes with the Ca2+ chelator BAPTA-AM before incubation
with torin2+rapamycin. Pre-treatment with BAPTA-AM inhibited
IL-6 secretion, indicating that Ca2+ is required for IL-6 secretion
(torin2+rapamycin 19756472% and bapta+torin2+rapamycin
4846137%) (Figure 6D). To assess if the torin2+rapamycin
treatment could affect ER Ca2+, we performed Ca2+ imaging of
drug-treated primary cultures loaded with the ratiometric dye
Fura-2. To evaluate ER Ca2+ content, we treated primary cultures
of astrocytes with the RyRs agonist 4-chloro-m-cresol (4-cmc) in
Ca2+-free conditions, to avoid Ca2+ influx from the media [40].
Bath application of 4-cmc resulted in a rapid transient Ca2+
increase (peak 0.8060.01 a.u., AUC 7262 a.u.), followed by
elevated intracellular Ca2+ levels (Figure 6D,E). The amplitude of
this Ca2+ response is a measure of the Ca2+ stored in the ER.
Stimulation with rapamycin increased the transient response
(Figure 6D,E(I)) (peak 0.8660.01 a.u.), in agreement with previous
data reporting that rapamycin increases RyRs open probability
without affecting the amount of Ca2+ stored in the ER (AUC
7963 a.u.) [41]. Importantly, torin2 treatment caused a reduction
of the peak induced by 4-cmc (Figure 6D,E(I)) (peak 0.76560.008
a.u.), suggesting a depletion of Ca2+ in the ER. Stimulation of
torin2+rapamycin treated astrocytes resulted in a significantly
smaller peak delayed in time (peak 0.6360.01 a.u.)
(Figure 6D,E(I)). Moreover, both torin2 (AUC 5364 a.u.) and
torin2+rapamycin (AUC 3662 a.u.) treatment also caused a
decrease of the area under the curve suggesting a decrease in ER
Ca2+ content or RyR expression (Figure 6D,E(II)).
Combined Treatment with Torin2 and Rapamycin has a
Small Temporary Effect on Mechanical Hypersensitivity
In order to examine if torin2+rapamycin treatment has a
positive effect on recovery from SCI, we treated injured animals
daily from day 15 to day 29 after injury with torin2 alone or in
combination with rapamycin. At this post-injury period the glia
scar was already mature and the endogenous IL-6 expression of
IL-6 was the same as sham animals. Even though both torin1 and
torin2 strongly inhibit mTOR, we decided to use torin2 because it
has a lower EC50, better bioavailability, and because we could
develop a special formulation designed to enable oral administra-
tion of the drug [36]. Torin2 treatment alone did not have any
effect on mechanical hypersensitivity or locomotion (Figure 7A,B).
In contrast, dual treatment with torin2 and rapamycin had a small
temporary effect on mechanical hypersensitivity during the
treatment window (Figure 7A), thus indicating a beneficial role
of the treatment.
Discussion
Spinal cord astrocytes respond to injury by forming a scar that
protects the healthy tissue and inhibits regeneration. Therefore,
the induction of regeneration promoting factors, such as IL-6 in
reactive astrocytes, may be beneficial for recovery after injury. We
found that SCI induces IL-6 in reactive astrocytes and that IL-6
levels decrease concomitantly with maturation of the glial scar. We
show that IL-6 production by astrocytes requires inhibition of the
PI3K-mTOR pathway, together with increased cytosolic Ca2+
astrocytes. A, Torin1 and rapamycin effects on IL-6 mRNA expression quantified by qPCR and expressed as percentage of vehicle treated cells. Data
presented as mean 6 SEM. *p,0.05 and ***p,0.001 for the comparison between vehicle and torin1 or torin1+rapamycin treated cells and n.s. (not
significant) for the comparison between torin1 and torin1+rapamycin treated cells by one-way ANOVA with Bonferroni’s post hoc test (N = 4–5 per
treatement). B, Torin2 and rapamycin effects on IL-6 mRNA expression quantified by qPCR and expressed as percentage of vehicle treated cells. Data
presented as mean 6 SEM. *p,0.05 and **p,0.01 for the comparison between vehicle and torin2 or torin2+rapamycin treated cells and n.s. (not
significant) for the comparison between torin2 and torin2+rapamycin treated cells by one-way ANOVA with Bonferroni’s post hoc test (N = 4–5 per
treatement). C, Lysates from untreated cells (GF free) and cell treated with vehicle, rapamycin, and torin2 were probed by immunoblotting with the
indicated antibodies. D, Optical densities of phospho-AKT serine 473 and threonine 308 bands normalized to levels of AKT in the lysates. Average
levels of phospho-AKT serine 473 and phospho-AKT threonine 308 shown as percentage of GF free condition. Data are presented as mean 6 SEM.
***p,0.001 and **p,0.01 for the comparison between vehicle and drug treated cells by one-way ANOVA with Bonferroni’s post hoc test (N = 4–5 per
treatement). E, Fragmented DNA labelled (tunel, green) in astrocytes treated with the indicated drugs or DNAseI as positive control. Astrocyte nuclei
were visualized by DAPI (blue) staining. F, Numbers of tunel positive cells. G, Lysates from vehicle and cells treated with rapamycin, torin2, torin2+
rapamycin, and staurosporine probed by immunoblotting with cleaved caspase-3 antibody and GAPDH.
doi:10.1371/journal.pone.0092649.g004
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concentration. Regulation of these pathways is achieved by
treating astrocytes with the PI3K-mTOR inhibitor torin2 together
with the RyRs opening facilitator, rapamycin. To determine if
torin2+rapamycin treatment is beneficial for recovery, we treated
injured animals when the scar had already been formed. Treated
animals showed a temporary improvement of mechanical hyper-
sensitivity limited to the drug treatment period.
In order to determine the time course of IL-6 induction after
SCI, we measured cytokine levels in plasma and spinal cords from
injured rats. In agreement with previous reports [42], we detected
increased IL-6 levels in both plasma and spinal cord parenchyma.
Interestingly, even though plasma levels returned to baseline one
week after injury, spinal cord IL-6 levels remained elevated. Using
in situ hybridization, we found that astrocytes, neurons and
Figure 5. NF-kB and MAPKs mediate the effect of PI3K-mTOR on IL-6 expression. Astrocytes treated with torin2 have elevated MAPK
signaling and express IL-6 in a NF-kB dependent manner. A, Bar graph showing luciferase activity (relative luciferase units R.L.U) expressed as
percentage of luciferase activity in vehicle treated cells. The grey bars represent astrocytes transfected with a plasmid in which wild type hIL-6
promoter (hIL6-wt) drives luciferase expression. The black bars represent cells transfected with a plasmid in which a hIL-6 promoter with a mutated
NF-kB binding site drives luciferase expression (hIL6-mut-NF-kB). Data are presented as mean 6 SEM. ***p,0.001 for the comparison between wt
and mut-NF-kB transfected astrocytes by two-way ANOVA with Bonferroni’s post hoc test (N = 3 per treatement). B, Lysates from vehicle, rapamycin,
and torin2 treated cells probed by immunoblotting with antibodies for phosphorylated and not phosphorylated forms of p38, ERK, and JNK. C,
Optical densities of the phospho-protein bands were normalized to the levels of the corresponding not phosphorylated proteins in the lysates and
expressed as percentage of vehicle treated cells. Average levels of phospho-ERK, phospho-JNK, and phospho-p38 shown as mean6 SEM. ***p,0.001
and *p,0.05 for the comparison between vehicle and drug treated cells by one-way ANOVA with Bonferroni’s post hoc test (N = 3 per treatement). D,
IL-6 mRNA expression quantified by real-time quantitative PCR and expressed as a percentage of expression in vehicle treated cells. Data are
presented as mean 6 SEM. ***p,0.001, for the comparison between torin2 and torin2+SB20358 treated cells by one-way ANOVA with Bonferroni’s
post hoc test (N = 4–5 per treatement).
doi:10.1371/journal.pone.0092649.g005
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Figure 6. PI3K-mTOR inhibition and increased cytosolic calcium are necessary for IL-6 secretion. Combined treatment with torin2 and
rapamycin induces IL-6 secretion by astrocytes as a result of PI3K-mTOR-AKT inhibition and increased intracellular calcium. A, Dose-response curve for
rapamycin, torin2, and torin2+rapamycin treatments. IL-6 protein secretion in the supernatant was measured from cultures of astrocytes incubated
with increasing concentrations (10 nM-1 mM) of torin2 or rapamycin alone or torin2 in combination with rapamycin (100 nM) (N = 3–7). ***p,0.001
for the comparison between torin2 (1 mM) and torin2 (1 mM)+rapamycin (100 nM) by one-way ANOVA with Bonferroni’s post hoc test. B, IL-6 protein
levels in the supernatant of astrocyte cultures treated for 24 hours with vehicle, rapamycin, torin1, torin2, LY294002, and AKT inhibitor alone or in
combination with rapamycin. Mean and SEM (N = 4–12 per treatement). *p,0.05, **p,0.01 and ***p,0.001 for the comparison between drug
treated cells by one-way ANOVA with Bonferroni’s post hoc tests. C, IL-6 levels in the supernatant for cells treated with torin2, torin2+ rapamycin,
torin2+ FK506, rapamycin, and FK506 (N = 3). **p,0.01 and ***p,0.001 for comparison between drug treated cells and vehicle and ##p,0.01 for
the comparison torin2+rapamycin and torin2+FK506 by one-way ANOVA with Bonferroni’s post hoc tests. D, IL-6 protein levels in the supernatant of
astrocyte cultures treated for 24 hours with vehicle, rapamycin, torin2, and rapamycin+torin2 with or without bapta-1am pre-treatment, expressed as
percentage of levels in vehicle treated cells (N = 4 per treatement). **p,0.01 comparison between torin2+rapamycin and torin2+rapamycin+bapta
treated cells by one-way ANOVA with Bonferroni’s post hoc tests. E, Representative Fura-2 calcium traces of 4-cmc treated cultures. Before stimulation
cells were incubated 24 hours with vehicle, rapamycin, torin2, or torin2+rapamycin. The black bar at 300 (s) indicates the time of 4-cmc stimulation.
Grey traces show the SEM of the response of all the cells analyzed in the experiment and the black trace corresponds to the average response. The
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microglia/macrophages are positive for IL-6 mRNA even though
there is no circulating IL-6, indicating that these cells are the local
producers of IL-6 in the phase following the first reaction to injury.
Thus, given that IL-6 can be produced by different cells at
different time points and the levels can be elevated either
systemically or only locally, it is plausible that IL-6 plays different
roles in pathology and repair depending on the time frame and
localization of expression. Importantly, spinal cord expression of
IL-6 returns to baseline once the scar is mature three weeks after
injury, and thus any positive effect of IL-6 on axonal regeneration
would no longer be in place. Hence, one strategy to promote
recovery after SCI even after the formation of a glial scar would be
to drive continued release of IL-6 to enhance IL-6-mediated
positive effect on regeneration. However, this requires an
understanding of the molecular mechanisms that regulate expres-
sion and release of IL-6 by astrocytes.
The PI3K-mTOR pathway is one regulatory element for
expression of inflammatory cytokines in immune cells [43], and
here we showed that it inhibits IL-6 expression in astrocytes.
PI3K-mTOR signaling converges on AKT, and it has been
demonstrated that active AKT has an inhibitory impact on
inflammatory genes in immune cells [44]. The negative impact on
cytokine production by AKT is mediated by inhibition of p38
and/or NF-kB activity [45,46]. Astrocytes treated with the PI3K-
mTOR inhibitor, torin2, have decreased AKT activity and
increased MAPKs and NF-kB activities. Interestingly, it has been
reported that p38 not only drives transcription of IL-6 by
promoting NF-kB activity, but also stabilizes IL-6 mRNA [47].
Our data show that in astrocytes the IL-6 mRNA level is regulated
by p38 and NF-kB activities with a molecular mechanism similar
to what has been previously reported for immune cells. Even
though PI3K-mTOR inhibition with torin2 increases IL-6 mRNA
in astrocytes, we show that IL-6 protein is not secreted in drug-
treated cultures. The lack of IL-6 in the supernatant may result
from inhibition of mRNA translation or lack of activation of
secretory pathways. It has recently been shown that soluble
cytokines like IL-6 are synthesized in the ER, transferred to the
Golgi, and then collected in small secretory vesicles that release
their cargo upon stimulation by fusing with the plasma membrane
[9]. Though not studied in astrocytes, Ca2+ buffering in mast cells
completely blocks IL-6 secretion [48]. Interestingly, when we
stimulated astrocytes with rapamycin or FK506, compounds,
which normally increase open probability and leakage from RYRs
on the ER, no increase in IL-6 secretion was found. However,
when the treatment was combined with PI3K-mTOR inhibitors,
IL-6 levels were readily detectable in the supernatant of astrocyte
cultures. This finding demonstrates that IL-6 secretion in
astrocytes requires both mRNA production and increased
intracellular Ca2+. Additionally, comparing FK506 and rapamycin
showed that FK506, in combination with torin2, is a stronger
inducer of IL-6. This may be explained by the ability of FK506 to
interact with calcineurin, releasing the inhibition of InsP3R in the
ER, which can result in higher intracellular Ca2+ and therefore a
stronger promotion of IL-6 secretion [16,17].
When astrocytes are stimulated with the RyRs agonist 4-cmc,
they release Ca2+ from the ER. We found that 4-cmc stimulation
of rapamycin-treated astrocytes induced a greater response,
compared to vehicle treated cells, thus confirming that rapamycin
can potentiate the effects of 4-cmc by increasing the open
probability of RyRs. Furthermore, 4-cmc stimulation of torin2
treated astrocytes induced a smaller response compared to vehicle.
We hypothesize that torin2 treatment caused a depletion of Ca2+
stored in the ER, and therefore not only reduced the response to 4-
cmc but also increased the cytosolic Ca2+ concentration. However,
we suggest that the increased cytosolic Ca2+ concentration was not
enough to induce RyRs opening via a Ca2+ -induced Ca2+ -release
mechanism, because torin2-treated cells still responded to 4-cmc
stimulation. Additionally, the torin2-induced increase in cytosolic
torin2+rapamycin graph shows a longer time scale to highlight the delay in the response (n = 49–78 cells per condition in a total of N = 3
experiments). F, Quantification of response (I) and area under the curve (A.U.C) (II) after stimulation with 4-cmc (n = 49–78 cells per condition in N = 3
experiments). **p,0.01 and ***p,0.001 for the comparison between torin2 and torin2+rapamycin with vehicle treated astrocytes. ###p,0.001
and ##p,0.01 for the comparison between torin2 and torin2+rapamycin treated cells by one-way ANOVA with Bonferroni’s post hoc tests.
doi:10.1371/journal.pone.0092649.g006
Figure 7. Combined treatment with torin2 and rapamycin improves mechanical hypersensitivity during treatment. Mechanical
hypersensitivity and locomotion of injured animals assessed for 6 weeks after contusion using von Frey filaments and the BBB scale, respectively. The
gray highlighted region represents the treatment period. A, Mechanical hypersensitivity expressed as changes in 50% withdrawal threshold (g) over
time. Repeated measures two way-anova show a significant effect of torin2+rapamycin (p,0.05) in the treatment window. Using bonferroni post-test
correction for multiple comparisons showed that torin2+rapamycin significantly reversed SCI-induced mechanical hypersensitivity at week three.
(*p,0.05). B, Hindlimb locomotor function assessed by the BBB locomotor rating scale. (Naı¨ve = 4, sham N = 6, pbs N = 6, torin2 N = 6, torin2+
rapamycin N = 8).
doi:10.1371/journal.pone.0092649.g007
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Ca2+ concentration is not enough to induce IL-6 secretion.
However, when rapamycin is added to torin2, the leakiness of
RyRs is increased and the cells do not respond to 4-cmc
stimulation. We suggest that the increase in cytosolic Ca2+
concentrations induced by torin2, in presence of rapamycin, is
sufficient to cause the opening of the RyRs, thus depleting the ER
from Ca2+ and inducing fusion of the IL-6 containing vesicles with
the plasma membrane (hypothesis depicted in Figure S3).
However, additional work is required in order to verify this
hypothesis.
Our data show that IL-6 secretion from astrocytes requires
PI3K-mTOR inhibition, and suggests that IL-6 mRNA is
translated even when mTOR, the master controller of protein
synthesis, is inhibited. mTOR has been shown to regulate CAP-
dependent translation of transcripts with oligopyrimidine (TOP/
TOP-like) motifs in the 59-untranslated region (59-UTR) [49]. The
IL-6 59-UTR does not match the characteristics of TOP/TOP-
like mRNAs, when the classification criteria illustrated by Thoreen
and co-workers are applied [50], suggesting CAP-independent
translation. Interestingly, translation of stress-related proteins is
also inhibited by the PI3K-mTOR pathway and is regulated
through a non-well characterized CAP-independent mechanism
[51].
Our data show that reactive astrocytes expressing IL-6 have a
low mTOR activity, and three weeks after injury, when IL-6 level
return to baseline, there is a concomitant increase in mTOR
activity. An important implication of our findings is that by using
torin2 and rapamycin, which block the PI3K-mTOR pathway
and increases intracellular Ca2+ concentrations, it is possible to
induce IL-6 release in reactive astrocytes. In light of the ability of
IL-6 to promote axonal regeneration [52,53], these drugs have the
potential to contribute to recovery after SCI. We tested this
hypothesis by treating rats subjected to SCI with torin2+
rapamycin for two weeks starting two weeks after injury. The
role of IL-6 in pain transmission is somewhat controversial and
there are only a few reports on the role of IL-6 in pain induced by
SCI [54]. We found a transient reversal in hypersensitivity during
the period of drug administration. However, because the drugs
were administered systemically we cannot exclude that the positive
effect of treatment was mediated through regulation of other
factors or cell types. Further studies are required in order to
determine this in detail. However, the positive effect noted during
the treatment window suggests that a prolonged or chronic
treatment might be more beneficial after SCI. However, recent
studies suggest that chronic treatment with mTOR inhibitors like
rapamycin may lead to insulin resistance [55,56]. However, a
longer period of treatment may be enough to promote a more
sustained reversal of mechanical hypersensitivity. Additional
studies are necessary in order to determine the optimal treatment
regiment.
In summary, we identified the PI3K-mTOR-Ca2+ pathway as
the molecular mechanism that regulates IL-6 expression and
secretion by astrocytes. We also identified that the combination of
torin2 and rapamycin may have beneficial effects on sensory
recovery after spinal cord injury, opening new possibilities for the
development of a therapy.
Supporting Information
Figure S1 Control in situ hybridization with IL-6 sense
mRNA probe. A, Cartoon depicting: (I) the 7 mm long segments
(rostral, caudal, epicenter) in which the injured spinal cord is
dissected for analysis. (II) Regions of the spinal cord sections
imaged. Dorsal horn (DH), dorsal column (DC), central canal
(CC), white matter (WM) and ventral horn (VH). B, IL-6 in situ
hybridization with sense IL-6 mRNA probe on sections from
rostral, caudal, and epicenter segments from spinal cord of naive
and injured animals 6 hours, 1, and 2 weeks post-injury. Scale
bar = 200 mm. C, High magnification images from sections of the
caudal segment shown in B from naive (20X) and 1 week injured
spinal cord animals (20X and 40X). Scale bar = 20 mm for 20X
and 40X. (N = 3 in each group)
(DOCX)
Figure S2 IL-6 is not expressed by immune cells in
white and gray matter. A, Immunolabeling of IL-6 (green) and
the microglia/macrophage marker OX-42 (magenta) of the white
matter of the caudal segment from spinal cords 1 week after injury.
B, Immunolabeling of IL-6 (green) and the microglia/macrophage
ED1 (magenta) of the white matter of the caudal segment from
spinal cords 1 week after injury. Scale bar = 20 mm. (N = 3 in each
group)
(DOCX)
Figure S3 Cartoon depicting the mechanism that regu-
lates IL-6 secretion in astrocytes. A, An astrocyte in naı¨ve
condition where PI3K-mTOR-AKT pathway is activated and
inhibits IL-6 expression. B, Inhibition of the PI3K-mTOR-AKT
pathway results in p38 activation and NF-kB-mediated transcrip-
tion of IL-6. Torin2 treatment also decreases ER Ca2+ content
suggesting an increase of Ca2+concentration in the cytosol.
However, the increase is not sufficient to cause IL-6 secretion.
C, A torin2 induced increase in cytosolic Ca2+ concentration is
sufficient to cause opening of the RyR2 when rapamycin is also
present in the cell. This causes a higher increase in Ca2+
concentration in the cytoplasm that is sufficient to induce IL-6
secretion.
(DOCX)
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